Pancreatitis is the most prevalent disease across the world and becoming a major public health concern. The global incidence of pancreatitis has increased. According to the Gastroenterology Journal, nearly 1.6 million cases have been reported annually in the world. Out of the total cases mortality remains high at over 3% and 13% cases are severe cases of pancreatitis.
Despite all diagnostic approaches, approximately 10% to 30% of patients have no identifiable causative agent observed. Innovations in the diagnostic field to detect the cause of Pancreatitis are essential. Revolutions in the treatment domain by launching novel medications and technology-based surgical instruments are required to improve patient health.
Moreover, pancreatitis is more common in males than females. According to the NIH report, men are 1.5 times more likely to suffer from pancreatitis than female. Also, the incidence of pancreatitis varies from region to region. In the United States, 210,000 patients are hospitalized annually due to pancreatitis.
Pancreatitis is the infection of the pancreas and destruction of pancreatic acinar cells caused by many factors like alcohol consumption, obesity, a mutation in the cationic trypsinogen gene, and blockage in the pancreatic duct. Common symptoms of pancreatitis include abdominal pain, fever, rapid pulse, weight loss, vomiting, and steatorrhea.
Pancreatitis is divided into acute pancreatitis with acute inflammatory responses and chronic pancreatitis which is characterized by stroma formation. The following table differentiates acute pancreatitis from chronic pancreatitis-
Differentiation Factors |
Acute Pancreatitis |
Chronic Pancreatitis |
Onset and duration |
It is a sudden onset with severe abdominal pain. It is acute and short-term. |
It is continuous inflammation of the pancreas. It is a long-term and progressive |
Cause |
It is caused due to gallstone blocks in the duct |
Caused due to inherited gene mutation. |
Age |
It can occur at any age |
It is present in the age group of 30 and 40 |
Complications |
Ulcerative colitis, pancreatic cancer. |
Chronic Pain, damage beta cells of pancreas. |
Incidence in U.S. |
13 to 45 per 100,000 people |
4.4 to 11.9 per 100,000 people |
Mortality Rate |
10% to 30% |
5% to 20% |
The development of new techniques and novel products for the treatment and diagnosis of Pancreatitis has been considered an essential part of increasing the opportunities for the industry player. As a result, it contributes to the outsourcing of the expanding items.
DiseaseLandscape Insights here assists in making informed judgments in the field of medical technology, medicines, and diagnostics, where different technologies and spectacular breakthroughs will alter the landscape, resulting in increased growth.
Diagnosis of Pancreatitis contains an assessment of various specific and non-specific biomarkers along with an estimation of pancreatic enzymes. Diagnosis of Pancreatitis is performed by a combination of various tests. After confirming the signs of patients with symptoms of Pancreatitis by evaluating medical history and physical examination, the following are the tests performed to detect Pancreatitis-
Blood tests for diagnosis of Pancreatitis involve the detection of levels of enzymes and a complete blood count to check the inflammation. Below are the three major biomarkers tests performed initially for the diagnosis of Pancreatitis
Serum Amylase- Serum amylase assay is performed to check the level of amylase secreted from the pancreas as an elevated level of amylase indicates the presence of Pancreatitis. However, in ~50% of pancreatitis cases serum amylase level is normal due to hypertriglyceridemia. Whereas, in ~80% of cases elevated serum amylase shows abdominal pains.
Lipase Enzyme Assay- Lipase enzyme assay is used to measure the amount of lipase enzyme secreted from the pancreas. Compared to the serum amylase test, lipase enzyme assay is preferred because it has a high sensitivity of 85% and specificity of 82% as stated by NIH.
Pancreatic Isoenzyme- Pancreatic isoenzyme assessment is more beneficial than the other two tests because it is increased in ~100% of cases of Pancreatitis. However, only in 10% of abdominal pain cases it is elevated.
Imaging tests for Pancreatitis are used to take an image of the pancreas to check for infection. Imaging tests help to diagnose both acute and chronic pancreatitis. The following imaging tests are performed to diagnose pancreatitis
Ultrasound- Ultrasound is used to create the images of structure of the pancreas by using a device called a Transducer. Clinical features of Pancreatitis like gallstones are detected using ultrasound. Physicians check for blockage in the bile flow by looking into ultrasound images.
Abdominal CT scan- A CT scan gives detailed pictures of the pancreas, bile ducts, and gall bladder. Detailed pictures help the clinician check the inflammation as well as blockages in the bile and pancreatic ducts. CT scan is used to differentiate between pancreatitis and pancreatic cancer.
Magnetic Resonance Cholangiopancreatography (MRCP)- MRCP uses a magnetic resonance machine to produce pictures of the pancreas, gall bladder, ducts, and soft tissue without X-ray. MRCP gives the exact cause of pancreatitis. Gallstones and stones in the biliary tree are diagnosed using MRCP as they cannot or are hard to detect by using ultrasound and abdominal CT scans.
Endoscopic Retrograde Cholangiopancreatography (ERCP)- ERCP is a type of endoscopy in which a small camera attached to a thin tube is inserted into the bile ducts. Physicians insert it till the duodenum part of the patient. ERCP is useful for checking the severity of pancreatitis.
The pancreatic function test is used to measure the response of the pancreas to a hormone called secretin which is secreted by the small intestine. This test is only available at some centers in the US.
Diagnostic tests are frequently carried out in public laboratories that are equipped with the appropriate and occasionally pricey equipment as well as staff members who are highly qualified to carry out the tests. The market for Pancreatitis diagnosis is highly crowded, and many industry players are providing their input in this field.
Below are the names of market competitors who are transforming healthcare with their advanced diagnostic approaches are listed below.
Diagnostic Market Player |
Products |
Cook Medical Incorporated |
22-G Wilson Cook® needle |
Olympus Corporation |
Olympus® |
FujiFilm Corporation |
Spec cPL® |
IDEXX Laboratories, Inc. |
Spec fPL® |
Roche Diagnostics |
Cobas 8000 Modular Analyzer Series |
Bio-Rad Laboratories |
Bio-Plex Pro™ |
Canon Medical System Corporation |
Aquilion Prime SP |
Siemens Healthineers |
SOMATOM Dual Source scanners |
GE Healthcare |
Revolution™ Apex Platform
|
Philips |
Big Bore RT™ |
Neusoft Medical System |
NeuViz Spiral CT Scanner |
United Imaging Healthcare |
uCT 780™ |
The cases of pancreatitis are increasing across the globe. Various treatment options are available in the market, but many researchers are working on novel therapies to treat Pancreatitis completely. The following are the treatment options available in the market.
Pancreatic enzyme pills are given to patients to help with digestion. Enzyme supplements increase nutrition absorption. Water soluble and fat-soluble vitamins are given to patients as due to Pancreatitis the body cannot absorb the nutrients including vitamins. Intravenous fluid is provided to patients for continuous hydration.
For pain management oral medication is given to the patient. Narcotics, muscle relaxants, and antidepressants are used to manage pain. Initial or mild stages of Pancreatitis are treated by medications. Severe cases need hospitalization.
Depending upon the severity of Pancreatitis, its cause, medical history of the patient, level of pain, anatomy of the patient, and other various factors surgery is performed. Surgery is required to remove the damaged or infected portion of the organ. During diagnosis if a patient is having gallstones, surgery is used to remove the gallstones and, in some cases, there is a need to remove the gall bladder.
However, in severe cases, the entire pancreas needs to be removed by surgical method. Removal of the entire pancreas is known as pancreatectomy. According to the American College of Surgeons, in around 90% of cases, pain is relieved of the patient after pancreatectomy.
Intra-abdominal hemorrhage, postoperative fistulas, diabetes, and some of the complications after surgery. As per the American College of Surgeons report, fistula occurs in 20 to 60% of patients whereas 10% of people develop the diabetes post-surgery. So, there is a need to develop more innovative surgical techniques in the treatment market.
DiseaseLandscape Insights provides extensive research on the treatment domain of pancreatitis disease to keep the stakeholders one step ahead in the market. DLI equips the knowledge about treatment options, novel drugs and techniques, products, and service contributions.
The global pancreatitis treatment market is highly competitive and owns a large market player with a global presence. The below table shows the market players who are reshaping the domain and driving innovations to improve healthcare outcomes.
Market Player |
Products |
Bioseutica B.V. |
TRYPSIN SE (PANCREATIN) |
Superior Supplements Manufacturing |
EFA COMPLEX |
Superior Supplements Manufacturing |
HCL COMPLEX |
Digestive Care Inc. |
PERTZYE® |
ELiT PHARMA |
Validus Vegan B Complex Softgel
|
Amkay Products Pvt. Ltd.
|
Scalpel and forceps, Absorbable sutures, and needle drivers |
Bard-Parker Company |
Scalpel and forceps, Absorbable sutures |
DiseaseLandscape Insights provides extensive research on healthcare products and market pyramids to the key players. DLI offers data about drug discovery, drug safety, efficacy supply chain collaboration, and long-term strategies for Pancreatitis dynamics.
DiseaseLandscape Insights offers comprehensive data management services for clinical and drug safety concerns. We also provide documents related to the research, novel drugs, and other medications. Stakeholders get knowledge of journal articles, abstracts for publications, instructional and marketing materials, and the websites of various medical organizations from the DLI services.
The business element of pancreatitis focuses on a variety of services and goods, ranging from management and prevention to further treatment and research. The following are the services provided to begin the process of removing the epidemic.
“Regulatory Program: Ensuring A Better Working Environment”
DiseaseLandscape Insights sorts the regulatory criteria from several nations for Pancreatitis. DLI offers empirical findings regarding risk assessment, monitoring, and regulatory adherence. Organizations and market participants prevent, manage, and react to flare-ups of Pancreatitis and protect the safety of affected people by exploring the DiseaseLandscape Insights services.
However, to control and prevent the outbreak of Pancreatitis various committees have been developed to offer guidelines to the public. Guidelines for the management of patients with severe acute Pancreatitis, with both written and graphical Editorials, were developed by the Clinical Guidelines Committee of the French Society of Anesthesia and Intensive Care Medicine (SFAR) in June 2021.
Regulatory organizations like the FDA, and the EU are in charge of approving and ensuring the security of medical equipment used in Pancreatitis diagnosis and treatment. For instance, the use of endoscopic tools in the detection and treatment of pancreatitis should be approved by regulatory bodies before they are marketed.
Moreover, in 2020, the COVID-19 pandemic prompted a sharp increase in telemedicine services. In order to allow for distant healthcare delivery, regulatory frameworks for telemedicine, including those pertaining to Pancreatitis treatment, were upgraded, and modified.
Several international industries are concentrating on manufacturing new products and enhancing the use of technology to improve current processes to increase their level of competition. Companies are also concentrating on ways to expand their product offerings, most commonly through collaborations, and regulatory approval for new drugs, medical research, and devices.
There are various companies like Johns Hopkins Medicine that are working on understanding the molecular and genetic factors involved in pancreatitis. The company is working on the development of targeted therapy to cure Pancreatitis caused due to genetic mutations.
Moreover, competitors like Cedars-Sinai Medical Center are working on the root cause of Pancreatitis and complications due to the disease. They are also working on innovations in minimally invasive surgical therapies for the treatment of pancreatitis.
Along with this GE Healthcare has developed the SIGNA MRI Systems as a diagnostic instrument for the diagnosis of pancreatitis. Launching such a product in the market has increased the overall revenue of the company and increased awareness about the product. Such inventions set the standard for other competitors who exist in the same industry and who want to enter the same field.
DiseaseLandscape Insights helps the stakeholders to stay stronger in the domain of pancreatitis by providing in-depth knowledge of existing market player, their innovations, plan of work, their growth structures, and collaborations and helps in selecting the proper position to grow continuously.
The global market is developing and evolving continuously due to advancements in the diagnostic and treatment field. Several industries are working on the development of less invasive surgery to treat pancreatitis patients. Research on cost-efficient diagnostic techniques is another landscape where many organizations are working.
However, several pharmaceutical companies are researching drugs that target the underlying cause and signs of Pancreatitis. Such medication includes pain management and inflammation-decreasing drugs. Market players have many opportunities in the development of targeted medications to treat Pancreatitis.
Moreover, novel techniques like endoscopic ultrasound and magnetic resonance cholangiopancreatography are emerging ways for the key players to grow financially. The launch of new innovative, cost-effective diagnostic kits is the era where industry players enter and generate tremendous revenue.
Organizations such as the National Pancreas Foundation (NPF) in the United States and the British Pancreatic Society (BPS) in the UK work to increase awareness, fund research, and provide support for individuals affected by Pancreatitis. These foundations promoted and enhanced the opportunities for key players to enter into the era of Pancreatitis.
Personalized medicines, novel therapy, and diagnostic kit manufacture have raised market size and hence the income of existing important players. Innovative technology, regulatory approval, government initiatives for patient health, and the introduction of laws and regulations in the research sector have expanded the influence of the market.
The government's increased emphasis on comparing the effectiveness of studies highlights the essential importance of clinical trials in the practice of evidence-based medicine and health care reform. One of the main aims of healthcare reform is realized by market participants thoroughly assessing medical therapy using clinical data.
The table below includes the study names of the ongoing clinical trials as well as the stages at which they are taking place.
Phase I |
Phase II |
Phase III |
Phase IV |
Evaluation of Pirfenidone as a Therapy in Patients with Predicted Moderate to Severe Acute Pancreatitis |
Corticosteroids to Reduce Inflammation in Severe Pancreatitis: A Randomized, Controlled Study |
A Randomized Trial Comparing Rectal Indomethacin Alone Versus a Combination of Rectal Indomethacin and Oral Tacrolimus for Post-ERCP Pancreatitis Prophylaxis |
Post ERCP Pancreatitis Prophylaxis, Effectiveness of Rectal Indomethacin vs Intravenous Ketorolac in the Pediatric Population |
Autologous Mesenchymal Stromal Cells and Islet Co-transplantation to Enhance Islet Survival and Function in Chronic Pancreatitis Patients Undergo Total Pancreatectomy and Islet Autotransplantation |
Effects of a Peripherally Acting µ-opioid Receptor Antagonist on Recurrent Acute Pancreatitis an Investigator-initiated, Randomized, Placebo-controlled, Double-blind Clinical Trial |
Effects of a Peripherally Acting µ-opioid Receptor Antagonist on Recurrent Acute Pancreatitis an Investigator-initiated, Randomized, Placebo-controlled, Double-blind Clinical Trial |
Aggressive Hydration with Lactated Ringer's Solution Versus Plasma Solution for the Prevention of Post ERCP (Endoscopic Retrograde Cholangiopancreatography) Pancreatitis: Multicenter, Double-Blind, Randomized Controlled Trial |
A Phase 1/2 Trial to Test the Safety of a CCK Receptor Antagonist, Proglumide, in Management of Chronic Pancreatitis Symptoms and Pain for 12 to 24 Months |
CRSPA: Phase I/II Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase |
Prophylaxis of Post-ERCP Acute Pancreatitis: A Randomized, Multicenter, Open-label Study Comparing Indomethacin Versus Indomethacin-ringer Lactate Combination |
|
STTEPP: Safety, Tolerability, and Dose Limiting Toxicity of Lacosamide in Patients with Painful Chronic Pancreatitis |
Evaluation of Pirfenidone as a Therapy in Patients with Predicted Moderate to Severe Acute Pancreatitis |
Comparative Effectiveness Between Rectally Administered Indomethacin and Pancreatic Stenting in the Prevention of Post Endoscopic Retrograde Cholangio-panceaticography (ERCP) Pancreatitis: A Randomized Trial |
|
CRSPA: Phase I/II Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase |
Initial Pain Management in Pediatric Pancreatitis: Opioid vs. Non-Opioid |
The Cancer of the Pancreas Screening-5 CAPS5) Study |
|
There are different market aspects concerning countries or regions for pancreatitis-specific diagnostic, treatment, and prevention markets. Because of the high prevalence of pancreatitis and difficulties related to cost-effective therapies for treating Pancreatitis, the government and various organizations have shown investments in research projects. Authorities have established centers for data collection and for the care of patients.
DLI aids in identifying the target market, driving marketing plans, and keeping market participants informed of emerging trends. DiseaseLandscape Insights helps manufacturers in developing and implementing effective medicines to halt and control Pancreatitis outbreaks by providing extensive market research.
This allows companies to do extensive R&D, learn about contract manufacturing organizations, discover raw material suppliers, and assure legal compliance for the business. DiseaseLandscape Insights (DLI) assists all market participants in gaining a stronger foothold in the pancreatitis disease sector.
How we can help?